GT Biopharma Appoints New Member to its Board of Directors

Core Insights - GT Biopharma, Inc. has appointed Hilary Kramer to its Board of Directors, replacing Bruce Wendel who is resigning [1][2] - The company is focused on developing innovative therapeutics based on its proprietary TriKE natural killer (NK) cell engager platform [1][4] - Hilary Kramer brings extensive experience in investment and strategic operations, having previously managed a $12 billion family office portfolio and served on multiple public company boards [2][3] Company Overview - GT Biopharma is a clinical stage biopharmaceutical company specializing in immuno-oncology therapeutic products [4] - The TriKE platform is designed to enhance the cancer-killing abilities of a patient's immune system's natural killer cells [4] - The company holds an exclusive worldwide license agreement with the University of Minnesota for the development and commercialization of therapies using TriKE technology [4]